CRO secures extended agreement with UK-based biotech firm

Preclinical contract research organisation (CRO), Aquila BioMedical — now part of Concept Life Sciences group, has secured an extended agreement with UK-based biotech firm, Macrophage Pharma, to support its preclinical immune-oncology programmes.

Aquila BioMedical

“We are delighted to announce our partnership with Macrophage Pharma. Our specialist immuno-oncology and multiplex histology capabilities are designed to enable our clients to make decisions earlier in the drug development process and potentially inform on clinical indications,” stated Clare Doris, chief operating officer at Aquila BioMedical. “Previous work with Macrophage Pharma has established innovative and tailored biology solutions, producing high value mechanistic data that will help progress its promising molecules to the clinic.”

Macrophage Pharma’s immuno-oncology programme with Aquila will incorporate a combination of in vitro, in vivo and ex vivo analyses. Through this programme, data will be generated that will enable Macrophage Pharma to identify the best preclinical candidate for investigational new drug (IND) selection for Phase I clinical trials.

Join the EPM Community for FREE today!

EPM Magazine is the essential information source for professionals involved in the formulation, development, manufacturing and supply of drugs and medicines in the pharmaceutical and biopharmaceutical industry.